ONCT Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Oncternal Therapeutics Inc

Watchlist Manager

Watchlist

Price: 0.5266 USD Market Closed

Market Cap: $1.6m

	Oncternal Therapeutics Inc NASDAQ:ONCT	US
	Ascendis Pharma A/S NASDAQ:ASND	DK
	Albis Leasing AG XETRA:ALG	DE

Profitability Summary

Oncternal Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Negative Operating Margin

-1 664%

Negative 3Y Average Operating Margin

-3 805%

Operating Margin is Increasing

-5 212% > -1 664%

Negative Net Margin

-1 600%

Negative 3Y Average Net Margin

-3 614%

Net Margin is Increasing

-4 986% > -1 600%

Negative Free Cash Flow Margin

-1 232%

Negative 3Y Average Free Cash Flow Margin

-2 891%

Free Cash Flow Margin is Increasing

-4 780% > -1 232%

Negative ROE

-150%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-4 429%

Declining ROIC

-2 850% > -12 357%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.